

Special Issue

Advances in Diagnosis and Treatment of Cancer in Digestive Organs

Message from the Guest Editor

Steady progress has been made in understanding the biology of cancer in the digestive system, yet effective and tolerable treatment as well as early detection and diagnosis remain highly unmet needs. Targeted therapy has been proven to benefit patients whose tumors harbor actionable biomarkers. The use of immunotherapy either as monotherapy or in combination with chemotherapy has been expanding in various tumor types and clinical settings. Emerging therapeutic modalities such as bispecific T-cell-engaging antibodies, chimeric antigen receptor T-cell therapy, a combination of immune checkpoint inhibitors, and natural killer cell therapy and vaccines have been the focus of intense clinical investigations. Tumor molecular profiling and tissue-based multi-omics analysis have led to the identification of molecular targets for precision therapy. This Special Issue aims to generate a collection of articles that focus on the recent advances of diagnosis and treatment in cancer of digestive organs, with the goal of advancing the frontiers in these challenging oncological diseases.

Guest Editor

Dr. Nelson Yee

Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033-0850, USA

Deadline for manuscript submissions

closed (31 October 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/143886

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).